Skip to main content

Table 3 Quantification of the immune response

From: Safety, tolerability and immunogenicity of an active anti-Aβ40 vaccine (ABvac40) in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase I trial

Treatment

Patient

Protocol

MSΔ

SDp

MSΔ/SDp

Signal adsorbeda (%)

Titres

Placebo

S002

IP

0.090

0.049

1.837

S004

IP

0.062

0.301

0.206

S005

IP

−0.033

0.055

−0.600

S010

IP

0.086

0.036

2.380

S015

AP

0.113

0.086

1.318

S017

AP

0.055

0.065

0.841

S020

AP

−0.076

0.118

−0.644

S028

AP

0.872

0.065

13.421

12.72b

ABvac40

S001

IP

0.249

0.071

3.507

83.00

30

S003

IP

0.315

0.064

4.927

96.72

10

S008

IP

0.129

0.397

0.326

S011

IP

1.852

0.066

28.061

90.95

810

S012

AP

0.190

0.099

1.919

S013

AP

3.635

0.097

37.474

95.54c

65,610

S014

AP

3.093

0.104

29.737

95.52

7290

S016

AP

2.156

0.099

21.778

95.22

270

S018

AP

0.626

0.037

16.298

105.22

90

S019

AP

3.526

0.099

35.616

99.63c

21,870

S021

AP

2.265

0.156

14.519

87.90

270

S022

AP

2.419

0.127

19.047

63.92

810

S023

AP

3.461

0.029

119.345

99.25c

65,610

S024

AP

1.011

0.103

9.816

72.40

90

S025

AP

2.852

0.112

25.464

93.71

810

S026

AP

3.230

0.104

31.058

96.81c

21,870

  1. Abbreviations: MSΔ Maximal signal increment (in optical density), SDp Average SD from all visits of each patient, IP Initial protocol, AP Amended protocol, Aβ Amyloid-β
  2. Non-responder patients are shown in bold
  3. aPre-adsorbed with 10−4 M Aβ33–40
  4. bThe low percentage of adsorption of this sample suggests non-specific signal
  5. cPre-adsorbed with 10−3 M Aβ33–40